Parallax Volatility Advisers, L.P. Bristol Myers Squibb CO Put Options Transaction History

Parallax Volatility Advisers, L.P.

$45.1 Billion
Q2 2024

Put Options

27 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$40.25 - $52.99 $6.96 Million - $9.17 Million	-173,000 Reduced 79.91%	43,500 $1.81 Million
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $8.08 Million - $9.17 Million	-168,500 Reduced 43.77%	216,500 $11.7 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $11.9 Million - $14.2 Million	245,700 Added 176.38%	385,000 $19.8 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $387,863 - $433,691	-6,700 Reduced 4.59%	139,300 $8.08 Million
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $29.8 Million - $33.1 Million	-468,000 Reduced 76.22%	146,000 $9.34 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $4.42 Million - $5.01 Million	67,200 Added 12.29%	614,000 $42.6 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $7.57 Million - $8.97 Million	110,600 Added 25.36%	546,800 $39.3 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $10,452 - $6.18 Million	-80,400 Reduced 15.56%	436,200 $31 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $30.4 Million - $33.4 Million	418,100 Added 424.47%	516,600 $39.8 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $1.33 Million - $1.6 Million	-21,700 Reduced 18.05%	98,500 $7.19 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $12.2 Million - $14.3 Million	-228,400 Reduced 65.52%	120,200 $7.49 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $10.3 Million - $12.1 Million	174,900 Added 100.69%	348,600 $20.6 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $14.7 Million - $16 Million	-237,900 Reduced 57.8%	173,700 $11.6 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $20.4 Million - $22.9 Million	-343,500 Reduced 45.49%	411,600 $26 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $34.4 Million - $39 Million	-596,200 Reduced 44.12%	755,100 $46.8 Million
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $49.3 Million - $54.6 Million	858,300 Added 174.1%	1,351,300 $81.5 Million
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $187 Million - $219 Million	-3,415,800 Reduced 87.39%	493,000 $29 Million
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $154 Million - $223 Million	3,314,100 Added 557.27%	3,908,800 $218 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $21.4 Million - $27.9 Million	434,000 Added 270.07%	594,700 $38.2 Million
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $8.98 Million - $10.6 Million	-210,000 Reduced 56.65%	160,700 $8.15 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $14.2 Million - $15.7 Million	-317,700 Reduced 46.15%	370,700 $16.8 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $4.07 Million - $4.86 Million	-90,300 Reduced 11.6%	688,400 $32.8 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $63.23 $4.86 Million - $6.3 Million	-99,700 Reduced 11.35%	778,700 $40.5 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $8.92 Million - $10.1 Million	-161,600 Reduced 15.54%	878,400 $54.5 Million
Q2 2018 Aug 14, 2018	BUY	$50.53 - $62.98 $47.8 Million - $59.5 Million	945,000 Added 994.74%	1,040,000 $57.6 Million
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $2.7 Million - $3.1 Million	-45,000 Reduced 32.14%	95,000 $6.01 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $8.39 Million - $9.15 Million	140,000	140,000 $8.58 Million

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

Vanguard Group Inc Valley Forge, PA

187M
Shares

$9.92 Billion
0.15% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$8.44 Billion
0.15% of portfolio
State Street Corp Boston, MA

91.4M
Shares

$4.86 Billion
0.17% of portfolio
Jpmorgan Chase & CO New York, NY

74.6M
Shares

$3.97 Billion
0.27% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

59.1M
Shares

$3.14 Billion
0.47% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.

Account